nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—CHRM3—ureter—uterine cancer	0.0418	0.139	CbGeAlD
Loxapine—CHRM3—muscle of abdomen—uterine cancer	0.0301	0.0998	CbGeAlD
Loxapine—HTR1E—myometrium—uterine cancer	0.0119	0.0395	CbGeAlD
Loxapine—HTR1B—artery—uterine cancer	0.0117	0.0387	CbGeAlD
Loxapine—HTR1D—artery—uterine cancer	0.0113	0.0374	CbGeAlD
Loxapine—HTR7—artery—uterine cancer	0.009	0.0298	CbGeAlD
Loxapine—CHRM3—exocrine gland—uterine cancer	0.00824	0.0273	CbGeAlD
Loxapine—CHRM5—epithelium—uterine cancer	0.00641	0.0212	CbGeAlD
Loxapine—HTR1E—female gonad—uterine cancer	0.00632	0.021	CbGeAlD
Loxapine—HTR2A—artery—uterine cancer	0.00561	0.0186	CbGeAlD
Loxapine—ADRA1B—renal system—uterine cancer	0.00543	0.018	CbGeAlD
Loxapine—DRD5—female reproductive system—uterine cancer	0.00531	0.0176	CbGeAlD
Loxapine—DRD5—female gonad—uterine cancer	0.00483	0.016	CbGeAlD
Loxapine—ADRA2C—myometrium—uterine cancer	0.00399	0.0132	CbGeAlD
Loxapine—Angiopathy—Progesterone—uterine cancer	0.00348	0.00524	CcSEcCtD
Loxapine—Hepatitis—Medroxyprogesterone Acetate—uterine cancer	0.00347	0.00523	CcSEcCtD
Loxapine—Mediastinal disorder—Progesterone—uterine cancer	0.00345	0.0052	CcSEcCtD
Loxapine—CHRM3—smooth muscle tissue—uterine cancer	0.00345	0.0114	CbGeAlD
Loxapine—HTR7—epithelium—uterine cancer	0.00341	0.0113	CbGeAlD
Loxapine—Alopecia—Progesterone—uterine cancer	0.00339	0.0051	CcSEcCtD
Loxapine—Dysphagia—Dactinomycin—uterine cancer	0.00339	0.0051	CcSEcCtD
Loxapine—SLC6A2—decidua—uterine cancer	0.00334	0.0111	CbGeAlD
Loxapine—CHRM3—renal system—uterine cancer	0.00332	0.011	CbGeAlD
Loxapine—HTR1A—renal system—uterine cancer	0.00331	0.011	CbGeAlD
Loxapine—ADRA1A—epithelium—uterine cancer	0.00329	0.0109	CbGeAlD
Loxapine—HTR7—smooth muscle tissue—uterine cancer	0.00329	0.0109	CbGeAlD
Loxapine—HTR1B—female reproductive system—uterine cancer	0.00329	0.0109	CbGeAlD
Loxapine—Tension—Progesterone—uterine cancer	0.00327	0.00493	CcSEcCtD
Loxapine—HRH1—myometrium—uterine cancer	0.00324	0.0108	CbGeAlD
Loxapine—Seborrhoeic dermatitis—Epirubicin—uterine cancer	0.00321	0.00484	CcSEcCtD
Loxapine—Muscle spasms—Progesterone—uterine cancer	0.00321	0.00483	CcSEcCtD
Loxapine—ADRA2A—myometrium—uterine cancer	0.00319	0.0106	CbGeAlD
Loxapine—HTR1D—female reproductive system—uterine cancer	0.00318	0.0105	CbGeAlD
Loxapine—HTR7—renal system—uterine cancer	0.00316	0.0105	CbGeAlD
Loxapine—Angiopathy—Medroxyprogesterone Acetate—uterine cancer	0.00315	0.00475	CcSEcCtD
Loxapine—HTR2C—female reproductive system—uterine cancer	0.00315	0.0104	CbGeAlD
Loxapine—Vision blurred—Progesterone—uterine cancer	0.00314	0.00474	CcSEcCtD
Loxapine—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00313	0.00472	CcSEcCtD
Loxapine—Tremor—Progesterone—uterine cancer	0.00313	0.00471	CcSEcCtD
Loxapine—ADRA2C—uterine cervix—uterine cancer	0.00311	0.0103	CbGeAlD
Loxapine—ADRB1—female reproductive system—uterine cancer	0.00309	0.0102	CbGeAlD
Loxapine—Alopecia—Medroxyprogesterone Acetate—uterine cancer	0.00307	0.00462	CcSEcCtD
Loxapine—ADRA1A—renal system—uterine cancer	0.00305	0.0101	CbGeAlD
Loxapine—Syncope—Progesterone—uterine cancer	0.00299	0.00451	CcSEcCtD
Loxapine—SLC6A4—female reproductive system—uterine cancer	0.00299	0.0099	CbGeAlD
Loxapine—CHRM1—female reproductive system—uterine cancer	0.00297	0.00986	CbGeAlD
Loxapine—Seborrhoeic dermatitis—Doxorubicin—uterine cancer	0.00297	0.00448	CcSEcCtD
Loxapine—Tension—Medroxyprogesterone Acetate—uterine cancer	0.00297	0.00447	CcSEcCtD
Loxapine—ADRA2C—decidua—uterine cancer	0.00296	0.00982	CbGeAlD
Loxapine—Dysgeusia—Medroxyprogesterone Acetate—uterine cancer	0.00296	0.00446	CcSEcCtD
Loxapine—Loss of consciousness—Progesterone—uterine cancer	0.00293	0.00442	CcSEcCtD
Loxapine—HRH2—lymph node—uterine cancer	0.00292	0.00966	CbGeAlD
Loxapine—Cough—Progesterone—uterine cancer	0.00291	0.00439	CcSEcCtD
Loxapine—ADRA2C—renal system—uterine cancer	0.00291	0.00964	CbGeAlD
Loxapine—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.00291	0.00438	CcSEcCtD
Loxapine—Convulsion—Progesterone—uterine cancer	0.00289	0.00436	CcSEcCtD
Loxapine—Hypertension—Progesterone—uterine cancer	0.00288	0.00434	CcSEcCtD
Loxapine—Chest pain—Progesterone—uterine cancer	0.00284	0.00428	CcSEcCtD
Loxapine—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.00283	0.00427	CcSEcCtD
Loxapine—Agranulocytosis—Dactinomycin—uterine cancer	0.00282	0.00424	CcSEcCtD
Loxapine—ADRA2C—endometrium—uterine cancer	0.00281	0.00932	CbGeAlD
Loxapine—Agitation—Medroxyprogesterone Acetate—uterine cancer	0.00278	0.00419	CcSEcCtD
Loxapine—Dry mouth—Progesterone—uterine cancer	0.00278	0.00419	CcSEcCtD
Loxapine—Confusional state—Progesterone—uterine cancer	0.00275	0.00414	CcSEcCtD
Loxapine—Oedema—Progesterone—uterine cancer	0.00272	0.0041	CcSEcCtD
Loxapine—ADRA2C—mammalian vulva—uterine cancer	0.00272	0.00902	CbGeAlD
Loxapine—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.00271	0.00409	CcSEcCtD
Loxapine—Hepatitis—Dactinomycin—uterine cancer	0.00271	0.00408	CcSEcCtD
Loxapine—Shock—Progesterone—uterine cancer	0.00268	0.00404	CcSEcCtD
Loxapine—Nervous system disorder—Progesterone—uterine cancer	0.00267	0.00402	CcSEcCtD
Loxapine—CHRM3—female reproductive system—uterine cancer	0.00266	0.00882	CbGeAlD
Loxapine—Tachycardia—Progesterone—uterine cancer	0.00266	0.004	CcSEcCtD
Loxapine—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	0.00266	0.004	CcSEcCtD
Loxapine—SLC6A2—female reproductive system—uterine cancer	0.00263	0.00872	CbGeAlD
Loxapine—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.00262	0.00395	CcSEcCtD
Loxapine—Liver injury—Epirubicin—uterine cancer	0.0026	0.00392	CcSEcCtD
Loxapine—ADRA2C—uterus—uterine cancer	0.00259	0.00859	CbGeAlD
Loxapine—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.00257	0.00388	CcSEcCtD
Loxapine—HRH1—epithelium—uterine cancer	0.00255	0.00844	CbGeAlD
Loxapine—Hypotension—Progesterone—uterine cancer	0.00254	0.00383	CcSEcCtD
Loxapine—HTR7—female reproductive system—uterine cancer	0.00253	0.0084	CbGeAlD
Loxapine—HRH1—uterine cervix—uterine cancer	0.00253	0.00837	CbGeAlD
Loxapine—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.00252	0.00379	CcSEcCtD
Loxapine—Amenorrhoea—Epirubicin—uterine cancer	0.00249	0.00375	CcSEcCtD
Loxapine—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.00249	0.00375	CcSEcCtD
Loxapine—ADRA2A—uterine cervix—uterine cancer	0.00248	0.00822	CbGeAlD
Loxapine—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.00247	0.00372	CcSEcCtD
Loxapine—Insomnia—Progesterone—uterine cancer	0.00246	0.00371	CcSEcCtD
Loxapine—HRH1—smooth muscle tissue—uterine cancer	0.00245	0.00814	CbGeAlD
Loxapine—Dysphagia—Etoposide—uterine cancer	0.00245	0.00369	CcSEcCtD
Loxapine—Paraesthesia—Progesterone—uterine cancer	0.00245	0.00368	CcSEcCtD
Loxapine—Dyspnoea—Progesterone—uterine cancer	0.00243	0.00366	CcSEcCtD
Loxapine—Shock—Medroxyprogesterone Acetate—uterine cancer	0.00243	0.00366	CcSEcCtD
Loxapine—CHRM3—female gonad—uterine cancer	0.00242	0.00803	CbGeAlD
Loxapine—Somnolence—Progesterone—uterine cancer	0.00242	0.00365	CcSEcCtD
Loxapine—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00242	0.00365	CcSEcCtD
Loxapine—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.00242	0.00364	CcSEcCtD
Loxapine—Bronchospasm—Etoposide—uterine cancer	0.00241	0.00363	CcSEcCtD
Loxapine—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.00241	0.00363	CcSEcCtD
Loxapine—Liver injury—Doxorubicin—uterine cancer	0.00241	0.00363	CcSEcCtD
Loxapine—HRH1—decidua—uterine cancer	0.00241	0.00798	CbGeAlD
Loxapine—Alopecia—Dactinomycin—uterine cancer	0.00239	0.00361	CcSEcCtD
Loxapine—ADRA2A—decidua—uterine cancer	0.00236	0.00783	CbGeAlD
Loxapine—Gastrointestinal disorder—Progesterone—uterine cancer	0.00235	0.00354	CcSEcCtD
Loxapine—Fatigue—Progesterone—uterine cancer	0.00235	0.00354	CcSEcCtD
Loxapine—Dyskinesia—Epirubicin—uterine cancer	0.00233	0.00351	CcSEcCtD
Loxapine—Constipation—Progesterone—uterine cancer	0.00233	0.00351	CcSEcCtD
Loxapine—Dysarthria—Epirubicin—uterine cancer	0.00231	0.00349	CcSEcCtD
Loxapine—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.00231	0.00347	CcSEcCtD
Loxapine—Amenorrhoea—Doxorubicin—uterine cancer	0.00231	0.00347	CcSEcCtD
Loxapine—HRH1—endometrium—uterine cancer	0.00228	0.00757	CbGeAlD
Loxapine—Feeling abnormal—Progesterone—uterine cancer	0.00224	0.00338	CcSEcCtD
Loxapine—ADRA2A—endometrium—uterine cancer	0.00224	0.00744	CbGeAlD
Loxapine—Gait disturbance—Epirubicin—uterine cancer	0.00224	0.00338	CcSEcCtD
Loxapine—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.00223	0.00336	CcSEcCtD
Loxapine—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.00222	0.00334	CcSEcCtD
Loxapine—HRH1—mammalian vulva—uterine cancer	0.00221	0.00732	CbGeAlD
Loxapine—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.0022	0.00331	CcSEcCtD
Loxapine—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.00219	0.00331	CcSEcCtD
Loxapine—Hepatocellular injury—Epirubicin—uterine cancer	0.00219	0.0033	CcSEcCtD
Loxapine—ADRA2A—mammalian vulva—uterine cancer	0.00217	0.00719	CbGeAlD
Loxapine—Dyskinesia—Doxorubicin—uterine cancer	0.00216	0.00325	CcSEcCtD
Loxapine—Renal failure—Etoposide—uterine cancer	0.00215	0.00323	CcSEcCtD
Loxapine—Dysarthria—Doxorubicin—uterine cancer	0.00214	0.00323	CcSEcCtD
Loxapine—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00213	0.00321	CcSEcCtD
Loxapine—Jaundice—Etoposide—uterine cancer	0.00213	0.00321	CcSEcCtD
Loxapine—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00213	0.00321	CcSEcCtD
Loxapine—HTR2A—epithelium—uterine cancer	0.00213	0.00705	CbGeAlD
Loxapine—Salivary hypersecretion—Epirubicin—uterine cancer	0.00213	0.0032	CcSEcCtD
Loxapine—ADRA2C—female gonad—uterine cancer	0.00212	0.00703	CbGeAlD
Loxapine—Leukopenia—Dactinomycin—uterine cancer	0.00211	0.00318	CcSEcCtD
Loxapine—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.00211	0.00318	CcSEcCtD
Loxapine—ADRA2C—vagina—uterine cancer	0.00211	0.00698	CbGeAlD
Loxapine—Gait disturbance—Doxorubicin—uterine cancer	0.00208	0.00313	CcSEcCtD
Loxapine—ADRA2A—uterus—uterine cancer	0.00207	0.00685	CbGeAlD
Loxapine—HTR2A—smooth muscle tissue—uterine cancer	0.00205	0.00679	CbGeAlD
Loxapine—Agranulocytosis—Etoposide—uterine cancer	0.00204	0.00307	CcSEcCtD
Loxapine—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00203	0.00306	CcSEcCtD
Loxapine—Hepatocellular injury—Doxorubicin—uterine cancer	0.00203	0.00305	CcSEcCtD
Loxapine—Dry eye—Epirubicin—uterine cancer	0.00202	0.00305	CcSEcCtD
Loxapine—Hypersensitivity—Progesterone—uterine cancer	0.00201	0.00302	CcSEcCtD
Loxapine—HTR2A—renal system—uterine cancer	0.00197	0.00654	CbGeAlD
Loxapine—Salivary hypersecretion—Doxorubicin—uterine cancer	0.00197	0.00296	CcSEcCtD
Loxapine—Asthenia—Progesterone—uterine cancer	0.00195	0.00294	CcSEcCtD
Loxapine—Hypoaesthesia—Etoposide—uterine cancer	0.00195	0.00294	CcSEcCtD
Loxapine—Pruritus—Progesterone—uterine cancer	0.00193	0.0029	CcSEcCtD
Loxapine—Oedema—Dactinomycin—uterine cancer	0.00192	0.0029	CcSEcCtD
Loxapine—HRH1—female reproductive system—uterine cancer	0.00189	0.00627	CbGeAlD
Loxapine—Thrombocytopenia—Dactinomycin—uterine cancer	0.00188	0.00284	CcSEcCtD
Loxapine—Dry eye—Doxorubicin—uterine cancer	0.00187	0.00282	CcSEcCtD
Loxapine—ADRA2A—female reproductive system—uterine cancer	0.00186	0.00616	CbGeAlD
Loxapine—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00182	0.00274	CcSEcCtD
Loxapine—Photosensitivity—Epirubicin—uterine cancer	0.00181	0.00273	CcSEcCtD
Loxapine—Dizziness—Progesterone—uterine cancer	0.0018	0.00271	CcSEcCtD
Loxapine—Angiopathy—Etoposide—uterine cancer	0.00178	0.00268	CcSEcCtD
Loxapine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00177	0.00267	CcSEcCtD
Loxapine—Mediastinal disorder—Etoposide—uterine cancer	0.00177	0.00266	CcSEcCtD
Loxapine—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00175	0.00263	CcSEcCtD
Loxapine—Alopecia—Etoposide—uterine cancer	0.00173	0.00261	CcSEcCtD
Loxapine—Vomiting—Progesterone—uterine cancer	0.00173	0.00261	CcSEcCtD
Loxapine—HRH1—female gonad—uterine cancer	0.00172	0.00571	CbGeAlD
Loxapine—Rash—Progesterone—uterine cancer	0.00172	0.00259	CcSEcCtD
Loxapine—Dermatitis—Progesterone—uterine cancer	0.00172	0.00258	CcSEcCtD
Loxapine—HRH1—vagina—uterine cancer	0.00171	0.00567	CbGeAlD
Loxapine—Headache—Progesterone—uterine cancer	0.00171	0.00257	CcSEcCtD
Loxapine—ADRA2A—female gonad—uterine cancer	0.00169	0.00561	CbGeAlD
Loxapine—ADRA2A—vagina—uterine cancer	0.00168	0.00557	CbGeAlD
Loxapine—Photosensitivity—Doxorubicin—uterine cancer	0.00167	0.00252	CcSEcCtD
Loxapine—Dysgeusia—Etoposide—uterine cancer	0.00167	0.00252	CcSEcCtD
Loxapine—Fatigue—Dactinomycin—uterine cancer	0.00166	0.0025	CcSEcCtD
Loxapine—Muscle spasms—Etoposide—uterine cancer	0.00164	0.00247	CcSEcCtD
Loxapine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00163	0.00246	CcSEcCtD
Loxapine—Cerebrovascular accident—Epirubicin—uterine cancer	0.00162	0.00244	CcSEcCtD
Loxapine—Nausea—Progesterone—uterine cancer	0.00162	0.00244	CcSEcCtD
Loxapine—Feeling abnormal—Dactinomycin—uterine cancer	0.00159	0.00239	CcSEcCtD
Loxapine—HTR2A—female reproductive system—uterine cancer	0.00158	0.00524	CbGeAlD
Loxapine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00157	0.00236	CcSEcCtD
Loxapine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00156	0.00234	CcSEcCtD
Loxapine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00155	0.00234	CcSEcCtD
Loxapine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00155	0.00233	CcSEcCtD
Loxapine—SLC6A2—lymph node—uterine cancer	0.00154	0.0051	CbGeAlD
Loxapine—Leukopenia—Etoposide—uterine cancer	0.00153	0.0023	CcSEcCtD
Loxapine—Loss of consciousness—Etoposide—uterine cancer	0.0015	0.00226	CcSEcCtD
Loxapine—Cerebrovascular accident—Doxorubicin—uterine cancer	0.0015	0.00226	CcSEcCtD
Loxapine—Cough—Etoposide—uterine cancer	0.00149	0.00224	CcSEcCtD
Loxapine—Convulsion—Etoposide—uterine cancer	0.00148	0.00223	CcSEcCtD
Loxapine—Hypertension—Etoposide—uterine cancer	0.00147	0.00222	CcSEcCtD
Loxapine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00147	0.00221	CcSEcCtD
Loxapine—Chest pain—Etoposide—uterine cancer	0.00145	0.00219	CcSEcCtD
Loxapine—Orthostatic hypotension—Epirubicin—uterine cancer	0.00145	0.00219	CcSEcCtD
Loxapine—HTR2A—vagina—uterine cancer	0.00143	0.00474	CbGeAlD
Loxapine—Hypersensitivity—Dactinomycin—uterine cancer	0.00142	0.00214	CcSEcCtD
Loxapine—Confusional state—Etoposide—uterine cancer	0.0014	0.00212	CcSEcCtD
Loxapine—Asthenia—Dactinomycin—uterine cancer	0.00138	0.00208	CcSEcCtD
Loxapine—Dysphagia—Epirubicin—uterine cancer	0.00137	0.00207	CcSEcCtD
Loxapine—Thrombocytopenia—Etoposide—uterine cancer	0.00136	0.00205	CcSEcCtD
Loxapine—ADRA2C—lymph node—uterine cancer	0.00136	0.00452	CbGeAlD
Loxapine—Tachycardia—Etoposide—uterine cancer	0.00136	0.00205	CcSEcCtD
Loxapine—Orthostatic hypotension—Doxorubicin—uterine cancer	0.00134	0.00202	CcSEcCtD
Loxapine—Hypotension—Etoposide—uterine cancer	0.0013	0.00196	CcSEcCtD
Loxapine—Dysphagia—Doxorubicin—uterine cancer	0.00127	0.00191	CcSEcCtD
Loxapine—Photosensitivity reaction—Epirubicin—uterine cancer	0.00125	0.00189	CcSEcCtD
Loxapine—Paraesthesia—Etoposide—uterine cancer	0.00125	0.00188	CcSEcCtD
Loxapine—Weight increased—Epirubicin—uterine cancer	0.00125	0.00188	CcSEcCtD
Loxapine—Weight decreased—Epirubicin—uterine cancer	0.00124	0.00187	CcSEcCtD
Loxapine—Dyspnoea—Etoposide—uterine cancer	0.00124	0.00187	CcSEcCtD
Loxapine—Somnolence—Etoposide—uterine cancer	0.00124	0.00187	CcSEcCtD
Loxapine—Drowsiness—Epirubicin—uterine cancer	0.00122	0.00184	CcSEcCtD
Loxapine—Vomiting—Dactinomycin—uterine cancer	0.00122	0.00184	CcSEcCtD
Loxapine—Rash—Dactinomycin—uterine cancer	0.00121	0.00183	CcSEcCtD
Loxapine—Renal failure—Epirubicin—uterine cancer	0.0012	0.00181	CcSEcCtD
Loxapine—Gastrointestinal disorder—Etoposide—uterine cancer	0.0012	0.00181	CcSEcCtD
Loxapine—Fatigue—Etoposide—uterine cancer	0.0012	0.00181	CcSEcCtD
Loxapine—Jaundice—Epirubicin—uterine cancer	0.00119	0.0018	CcSEcCtD
Loxapine—Constipation—Etoposide—uterine cancer	0.00119	0.00179	CcSEcCtD
Loxapine—Photosensitivity reaction—Doxorubicin—uterine cancer	0.00116	0.00175	CcSEcCtD
Loxapine—Weight increased—Doxorubicin—uterine cancer	0.00116	0.00174	CcSEcCtD
Loxapine—Weight decreased—Doxorubicin—uterine cancer	0.00115	0.00173	CcSEcCtD
Loxapine—Feeling abnormal—Etoposide—uterine cancer	0.00115	0.00173	CcSEcCtD
Loxapine—Nausea—Dactinomycin—uterine cancer	0.00114	0.00172	CcSEcCtD
Loxapine—Agranulocytosis—Epirubicin—uterine cancer	0.00114	0.00172	CcSEcCtD
Loxapine—Drowsiness—Doxorubicin—uterine cancer	0.00113	0.00171	CcSEcCtD
Loxapine—Renal failure—Doxorubicin—uterine cancer	0.00111	0.00168	CcSEcCtD
Loxapine—HRH1—lymph node—uterine cancer	0.00111	0.00367	CbGeAlD
Loxapine—Jaundice—Doxorubicin—uterine cancer	0.0011	0.00166	CcSEcCtD
Loxapine—Hepatitis—Epirubicin—uterine cancer	0.0011	0.00166	CcSEcCtD
Loxapine—Hypoaesthesia—Epirubicin—uterine cancer	0.00109	0.00165	CcSEcCtD
Loxapine—ADRA2A—lymph node—uterine cancer	0.00109	0.0036	CbGeAlD
Loxapine—Agranulocytosis—Doxorubicin—uterine cancer	0.00106	0.00159	CcSEcCtD
Loxapine—Hypersensitivity—Etoposide—uterine cancer	0.00103	0.00155	CcSEcCtD
Loxapine—Hepatitis—Doxorubicin—uterine cancer	0.00102	0.00153	CcSEcCtD
Loxapine—Hypoaesthesia—Doxorubicin—uterine cancer	0.00101	0.00152	CcSEcCtD
Loxapine—Asthenia—Etoposide—uterine cancer	0.001	0.00151	CcSEcCtD
Loxapine—Angiopathy—Epirubicin—uterine cancer	0.000997	0.0015	CcSEcCtD
Loxapine—Mediastinal disorder—Epirubicin—uterine cancer	0.000991	0.00149	CcSEcCtD
Loxapine—Pruritus—Etoposide—uterine cancer	0.000986	0.00148	CcSEcCtD
Loxapine—Alopecia—Epirubicin—uterine cancer	0.000971	0.00146	CcSEcCtD
Loxapine—Tension—Epirubicin—uterine cancer	0.000939	0.00141	CcSEcCtD
Loxapine—Dysgeusia—Epirubicin—uterine cancer	0.000937	0.00141	CcSEcCtD
Loxapine—Angiopathy—Doxorubicin—uterine cancer	0.000923	0.00139	CcSEcCtD
Loxapine—Dizziness—Etoposide—uterine cancer	0.000921	0.00139	CcSEcCtD
Loxapine—Muscle spasms—Epirubicin—uterine cancer	0.00092	0.00139	CcSEcCtD
Loxapine—Mediastinal disorder—Doxorubicin—uterine cancer	0.000917	0.00138	CcSEcCtD
Loxapine—Vision blurred—Epirubicin—uterine cancer	0.000902	0.00136	CcSEcCtD
Loxapine—Alopecia—Doxorubicin—uterine cancer	0.000899	0.00135	CcSEcCtD
Loxapine—Vomiting—Etoposide—uterine cancer	0.000886	0.00133	CcSEcCtD
Loxapine—Agitation—Epirubicin—uterine cancer	0.000879	0.00132	CcSEcCtD
Loxapine—Rash—Etoposide—uterine cancer	0.000878	0.00132	CcSEcCtD
Loxapine—Dermatitis—Etoposide—uterine cancer	0.000878	0.00132	CcSEcCtD
Loxapine—Headache—Etoposide—uterine cancer	0.000873	0.00131	CcSEcCtD
Loxapine—Tension—Doxorubicin—uterine cancer	0.000869	0.00131	CcSEcCtD
Loxapine—Dysgeusia—Doxorubicin—uterine cancer	0.000867	0.00131	CcSEcCtD
Loxapine—Syncope—Epirubicin—uterine cancer	0.000858	0.00129	CcSEcCtD
Loxapine—Leukopenia—Epirubicin—uterine cancer	0.000857	0.00129	CcSEcCtD
Loxapine—Muscle spasms—Doxorubicin—uterine cancer	0.000851	0.00128	CcSEcCtD
Loxapine—Loss of consciousness—Epirubicin—uterine cancer	0.000841	0.00127	CcSEcCtD
Loxapine—Cough—Epirubicin—uterine cancer	0.000835	0.00126	CcSEcCtD
Loxapine—Vision blurred—Doxorubicin—uterine cancer	0.000834	0.00126	CcSEcCtD
Loxapine—Convulsion—Epirubicin—uterine cancer	0.000829	0.00125	CcSEcCtD
Loxapine—Nausea—Etoposide—uterine cancer	0.000828	0.00125	CcSEcCtD
Loxapine—Hypertension—Epirubicin—uterine cancer	0.000826	0.00124	CcSEcCtD
Loxapine—Chest pain—Epirubicin—uterine cancer	0.000815	0.00123	CcSEcCtD
Loxapine—Agitation—Doxorubicin—uterine cancer	0.000814	0.00123	CcSEcCtD
Loxapine—Dry mouth—Epirubicin—uterine cancer	0.000797	0.0012	CcSEcCtD
Loxapine—Syncope—Doxorubicin—uterine cancer	0.000794	0.0012	CcSEcCtD
Loxapine—Leukopenia—Doxorubicin—uterine cancer	0.000793	0.00119	CcSEcCtD
Loxapine—Confusional state—Epirubicin—uterine cancer	0.000787	0.00119	CcSEcCtD
Loxapine—Oedema—Epirubicin—uterine cancer	0.000781	0.00118	CcSEcCtD
Loxapine—Loss of consciousness—Doxorubicin—uterine cancer	0.000778	0.00117	CcSEcCtD
Loxapine—Cough—Doxorubicin—uterine cancer	0.000773	0.00116	CcSEcCtD
Loxapine—Shock—Epirubicin—uterine cancer	0.000768	0.00116	CcSEcCtD
Loxapine—Convulsion—Doxorubicin—uterine cancer	0.000767	0.00116	CcSEcCtD
Loxapine—Nervous system disorder—Epirubicin—uterine cancer	0.000766	0.00115	CcSEcCtD
Loxapine—Thrombocytopenia—Epirubicin—uterine cancer	0.000765	0.00115	CcSEcCtD
Loxapine—Hypertension—Doxorubicin—uterine cancer	0.000764	0.00115	CcSEcCtD
Loxapine—Tachycardia—Epirubicin—uterine cancer	0.000762	0.00115	CcSEcCtD
Loxapine—Chest pain—Doxorubicin—uterine cancer	0.000754	0.00114	CcSEcCtD
Loxapine—Dry mouth—Doxorubicin—uterine cancer	0.000737	0.00111	CcSEcCtD
Loxapine—Hypotension—Epirubicin—uterine cancer	0.00073	0.0011	CcSEcCtD
Loxapine—Confusional state—Doxorubicin—uterine cancer	0.000729	0.0011	CcSEcCtD
Loxapine—Oedema—Doxorubicin—uterine cancer	0.000723	0.00109	CcSEcCtD
Loxapine—Shock—Doxorubicin—uterine cancer	0.000711	0.00107	CcSEcCtD
Loxapine—Nervous system disorder—Doxorubicin—uterine cancer	0.000709	0.00107	CcSEcCtD
Loxapine—Thrombocytopenia—Doxorubicin—uterine cancer	0.000708	0.00107	CcSEcCtD
Loxapine—Insomnia—Epirubicin—uterine cancer	0.000706	0.00106	CcSEcCtD
Loxapine—Tachycardia—Doxorubicin—uterine cancer	0.000705	0.00106	CcSEcCtD
Loxapine—Paraesthesia—Epirubicin—uterine cancer	0.000701	0.00106	CcSEcCtD
Loxapine—Dyspnoea—Epirubicin—uterine cancer	0.000696	0.00105	CcSEcCtD
Loxapine—Somnolence—Epirubicin—uterine cancer	0.000694	0.00105	CcSEcCtD
Loxapine—Hypotension—Doxorubicin—uterine cancer	0.000675	0.00102	CcSEcCtD
Loxapine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000674	0.00102	CcSEcCtD
Loxapine—Fatigue—Epirubicin—uterine cancer	0.000673	0.00101	CcSEcCtD
Loxapine—Constipation—Epirubicin—uterine cancer	0.000668	0.00101	CcSEcCtD
Loxapine—Insomnia—Doxorubicin—uterine cancer	0.000654	0.000985	CcSEcCtD
Loxapine—Paraesthesia—Doxorubicin—uterine cancer	0.000649	0.000977	CcSEcCtD
Loxapine—Dyspnoea—Doxorubicin—uterine cancer	0.000644	0.000971	CcSEcCtD
Loxapine—Feeling abnormal—Epirubicin—uterine cancer	0.000644	0.000969	CcSEcCtD
Loxapine—Somnolence—Doxorubicin—uterine cancer	0.000642	0.000968	CcSEcCtD
Loxapine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000624	0.00094	CcSEcCtD
Loxapine—Fatigue—Doxorubicin—uterine cancer	0.000623	0.000939	CcSEcCtD
Loxapine—Constipation—Doxorubicin—uterine cancer	0.000618	0.000931	CcSEcCtD
Loxapine—Feeling abnormal—Doxorubicin—uterine cancer	0.000595	0.000897	CcSEcCtD
Loxapine—Hypersensitivity—Epirubicin—uterine cancer	0.000575	0.000867	CcSEcCtD
Loxapine—Asthenia—Epirubicin—uterine cancer	0.00056	0.000844	CcSEcCtD
Loxapine—Pruritus—Epirubicin—uterine cancer	0.000553	0.000832	CcSEcCtD
Loxapine—Hypersensitivity—Doxorubicin—uterine cancer	0.000532	0.000802	CcSEcCtD
Loxapine—Asthenia—Doxorubicin—uterine cancer	0.000518	0.000781	CcSEcCtD
Loxapine—Dizziness—Epirubicin—uterine cancer	0.000516	0.000778	CcSEcCtD
Loxapine—Pruritus—Doxorubicin—uterine cancer	0.000511	0.00077	CcSEcCtD
Loxapine—Vomiting—Epirubicin—uterine cancer	0.000497	0.000748	CcSEcCtD
Loxapine—Rash—Epirubicin—uterine cancer	0.000492	0.000742	CcSEcCtD
Loxapine—Dermatitis—Epirubicin—uterine cancer	0.000492	0.000741	CcSEcCtD
Loxapine—Headache—Epirubicin—uterine cancer	0.000489	0.000737	CcSEcCtD
Loxapine—Dizziness—Doxorubicin—uterine cancer	0.000478	0.00072	CcSEcCtD
Loxapine—Nausea—Epirubicin—uterine cancer	0.000464	0.000699	CcSEcCtD
Loxapine—Vomiting—Doxorubicin—uterine cancer	0.000459	0.000692	CcSEcCtD
Loxapine—Rash—Doxorubicin—uterine cancer	0.000456	0.000686	CcSEcCtD
Loxapine—Dermatitis—Doxorubicin—uterine cancer	0.000455	0.000686	CcSEcCtD
Loxapine—Headache—Doxorubicin—uterine cancer	0.000453	0.000682	CcSEcCtD
Loxapine—Nausea—Doxorubicin—uterine cancer	0.000429	0.000647	CcSEcCtD
Loxapine—HTR1A—Signaling Pathways—CTNNB1—uterine cancer	5.44e-06	0.000157	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PTEN—uterine cancer	5.43e-06	0.000157	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—NRAS—uterine cancer	5.42e-06	0.000157	CbGpPWpGaD
Loxapine—ADRA1B—GPCR downstream signaling—AKT1—uterine cancer	5.42e-06	0.000157	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—PIK3CA—uterine cancer	5.42e-06	0.000157	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—KRAS—uterine cancer	5.41e-06	0.000157	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CTNNB1—uterine cancer	5.41e-06	0.000157	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—AKT1—uterine cancer	5.4e-06	0.000157	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—AKT1—uterine cancer	5.38e-06	0.000156	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—ERBB2—uterine cancer	5.37e-06	0.000155	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—PIK3CA—uterine cancer	5.37e-06	0.000155	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—ERBB2—uterine cancer	5.36e-06	0.000155	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—AKT1—uterine cancer	5.35e-06	0.000155	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—PIK3CA—uterine cancer	5.35e-06	0.000155	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—AKT1—uterine cancer	5.34e-06	0.000155	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—KRAS—uterine cancer	5.34e-06	0.000155	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—ERBB2—uterine cancer	5.34e-06	0.000155	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—ERBB2—uterine cancer	5.32e-06	0.000154	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PTEN—uterine cancer	5.3e-06	0.000153	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EP300—uterine cancer	5.28e-06	0.000153	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PTEN—uterine cancer	5.27e-06	0.000153	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—ERBB2—uterine cancer	5.27e-06	0.000153	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CTNNB1—uterine cancer	5.26e-06	0.000152	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—ERBB2—uterine cancer	5.26e-06	0.000152	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—KRAS—uterine cancer	5.26e-06	0.000152	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EP300—uterine cancer	5.23e-06	0.000152	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—KRAS—uterine cancer	5.18e-06	0.00015	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CTNNB1—uterine cancer	5.18e-06	0.00015	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—EP300—uterine cancer	5.18e-06	0.00015	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CXCL8—uterine cancer	5.17e-06	0.00015	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—AKT1—uterine cancer	5.17e-06	0.00015	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—AKT1—uterine cancer	5.14e-06	0.000149	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—HRAS—uterine cancer	5.14e-06	0.000149	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PTEN—uterine cancer	5.13e-06	0.000149	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CXCL8—uterine cancer	5.09e-06	0.000147	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CXCL8—uterine cancer	5.08e-06	0.000147	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CXCL8—uterine cancer	5.06e-06	0.000147	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—HRAS—uterine cancer	5.06e-06	0.000146	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EP300—uterine cancer	5.05e-06	0.000146	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CDKN1B—uterine cancer	5.05e-06	0.000146	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—PIK3CA—uterine cancer	5.05e-06	0.000146	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CXCL8—uterine cancer	5.05e-06	0.000146	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—HRAS—uterine cancer	5.05e-06	0.000146	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PTEN—uterine cancer	5.05e-06	0.000146	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—PIK3CA—uterine cancer	5.04e-06	0.000146	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—HRAS—uterine cancer	5.03e-06	0.000146	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EP300—uterine cancer	5.03e-06	0.000146	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—HRAS—uterine cancer	5.01e-06	0.000145	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—PIK3CA—uterine cancer	5.01e-06	0.000145	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—VEGFA—uterine cancer	5e-06	0.000145	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—AKT1—uterine cancer	5e-06	0.000145	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CXCL8—uterine cancer	5e-06	0.000145	CbGpPWpGaD
Loxapine—DRD2—GPCR downstream signaling—AKT1—uterine cancer	5e-06	0.000145	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CXCL8—uterine cancer	4.98e-06	0.000144	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PTEN—uterine cancer	4.98e-06	0.000144	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—PIK3CA—uterine cancer	4.97e-06	0.000144	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CDKN1B—uterine cancer	4.97e-06	0.000144	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—HRAS—uterine cancer	4.97e-06	0.000144	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—KRAS—uterine cancer	4.97e-06	0.000144	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CDKN1B—uterine cancer	4.96e-06	0.000144	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—VEGFA—uterine cancer	4.96e-06	0.000144	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—HRAS—uterine cancer	4.95e-06	0.000143	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CDKN1B—uterine cancer	4.94e-06	0.000143	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—NRAS—uterine cancer	4.94e-06	0.000143	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CDKN1B—uterine cancer	4.93e-06	0.000143	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—AKT1—uterine cancer	4.92e-06	0.000143	CbGpPWpGaD
Loxapine—HTR2A—GPCR downstream signaling—AKT1—uterine cancer	4.92e-06	0.000142	CbGpPWpGaD
Loxapine—HRH1—GPCR downstream signaling—AKT1—uterine cancer	4.91e-06	0.000142	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—PIK3CA—uterine cancer	4.91e-06	0.000142	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—NRAS—uterine cancer	4.9e-06	0.000142	CbGpPWpGaD
Loxapine—CHRM1—GPCR downstream signaling—AKT1—uterine cancer	4.89e-06	0.000142	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EP300—uterine cancer	4.89e-06	0.000142	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TP53—uterine cancer	4.89e-06	0.000142	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—ERBB2—uterine cancer	4.88e-06	0.000141	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CDKN1B—uterine cancer	4.88e-06	0.000141	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TP53—uterine cancer	4.88e-06	0.000141	CbGpPWpGaD
Loxapine—CHRM3—GPCR downstream signaling—AKT1—uterine cancer	4.88e-06	0.000141	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CDKN1B—uterine cancer	4.87e-06	0.000141	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TP53—uterine cancer	4.85e-06	0.00014	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—PIK3CA—uterine cancer	4.83e-06	0.00014	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—AKT1—uterine cancer	4.83e-06	0.00014	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—AKT1—uterine cancer	4.82e-06	0.000139	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EP300—uterine cancer	4.81e-06	0.000139	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—VEGFA—uterine cancer	4.79e-06	0.000139	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CTNNB1—uterine cancer	4.77e-06	0.000138	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—PIK3CA—uterine cancer	4.76e-06	0.000138	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—VEGFA—uterine cancer	4.76e-06	0.000138	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—EP300—uterine cancer	4.75e-06	0.000138	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TP53—uterine cancer	4.75e-06	0.000137	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—KRAS—uterine cancer	4.73e-06	0.000137	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—NRAS—uterine cancer	4.73e-06	0.000137	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—NRAS—uterine cancer	4.7e-06	0.000136	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CTNNB1—uterine cancer	4.7e-06	0.000136	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CTNNB1—uterine cancer	4.69e-06	0.000136	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—HRAS—uterine cancer	4.67e-06	0.000135	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CTNNB1—uterine cancer	4.67e-06	0.000135	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—uterine cancer	4.67e-06	0.000135	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—KRAS—uterine cancer	4.67e-06	0.000135	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—HRAS—uterine cancer	4.67e-06	0.000135	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CTNNB1—uterine cancer	4.66e-06	0.000135	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PTEN—uterine cancer	4.65e-06	0.000135	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—HRAS—uterine cancer	4.64e-06	0.000134	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCL8—uterine cancer	4.63e-06	0.000134	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—uterine cancer	4.63e-06	0.000134	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CTNNB1—uterine cancer	4.61e-06	0.000134	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—uterine cancer	4.61e-06	0.000133	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—HRAS—uterine cancer	4.6e-06	0.000133	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CTNNB1—uterine cancer	4.6e-06	0.000133	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PTEN—uterine cancer	4.58e-06	0.000133	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NRAS—uterine cancer	4.57e-06	0.000132	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PTEN—uterine cancer	4.57e-06	0.000132	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—PIK3CA—uterine cancer	4.56e-06	0.000132	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—uterine cancer	4.56e-06	0.000132	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PTEN—uterine cancer	4.55e-06	0.000132	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—HRAS—uterine cancer	4.54e-06	0.000131	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—uterine cancer	4.54e-06	0.000131	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PTEN—uterine cancer	4.54e-06	0.000131	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1B—uterine cancer	4.52e-06	0.000131	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NRAS—uterine cancer	4.5e-06	0.00013	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PTEN—uterine cancer	4.49e-06	0.00013	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PTEN—uterine cancer	4.48e-06	0.00013	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—uterine cancer	4.47e-06	0.00013	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—HRAS—uterine cancer	4.47e-06	0.000129	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—uterine cancer	4.47e-06	0.000129	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—uterine cancer	4.46e-06	0.000129	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—uterine cancer	4.44e-06	0.000129	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EP300—uterine cancer	4.44e-06	0.000129	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—uterine cancer	4.43e-06	0.000128	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—uterine cancer	4.41e-06	0.000128	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—HRAS—uterine cancer	4.41e-06	0.000128	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—uterine cancer	4.38e-06	0.000127	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—uterine cancer	4.37e-06	0.000127	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EP300—uterine cancer	4.37e-06	0.000126	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EP300—uterine cancer	4.36e-06	0.000126	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—PIK3CA—uterine cancer	4.35e-06	0.000126	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EP300—uterine cancer	4.34e-06	0.000126	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EP300—uterine cancer	4.33e-06	0.000125	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PIK3CA—uterine cancer	4.33e-06	0.000125	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—PIK3CA—uterine cancer	4.29e-06	0.000124	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EP300—uterine cancer	4.29e-06	0.000124	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EP300—uterine cancer	4.27e-06	0.000124	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CTNNB1—uterine cancer	4.27e-06	0.000124	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KRAS—uterine cancer	4.25e-06	0.000123	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—HRAS—uterine cancer	4.22e-06	0.000122	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KRAS—uterine cancer	4.21e-06	0.000122	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—uterine cancer	4.21e-06	0.000122	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—uterine cancer	4.2e-06	0.000122	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PTEN—uterine cancer	4.16e-06	0.000121	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NRAS—uterine cancer	4.15e-06	0.00012	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—uterine cancer	4.15e-06	0.00012	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—uterine cancer	4.13e-06	0.00012	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—uterine cancer	4.13e-06	0.00012	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—uterine cancer	4.13e-06	0.000119	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—uterine cancer	4.12e-06	0.000119	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—uterine cancer	4.11e-06	0.000119	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—uterine cancer	4.1e-06	0.000119	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—uterine cancer	4.09e-06	0.000119	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NRAS—uterine cancer	4.08e-06	0.000118	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NRAS—uterine cancer	4.08e-06	0.000118	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KRAS—uterine cancer	4.07e-06	0.000118	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—uterine cancer	4.06e-06	0.000118	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NRAS—uterine cancer	4.06e-06	0.000118	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—uterine cancer	4.06e-06	0.000118	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NRAS—uterine cancer	4.05e-06	0.000117	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—uterine cancer	4.05e-06	0.000117	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KRAS—uterine cancer	4.05e-06	0.000117	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—HRAS—uterine cancer	4.02e-06	0.000116	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NRAS—uterine cancer	4.01e-06	0.000116	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—uterine cancer	4.01e-06	0.000116	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NRAS—uterine cancer	4e-06	0.000116	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EP300—uterine cancer	3.97e-06	0.000115	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—HRAS—uterine cancer	3.97e-06	0.000115	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—uterine cancer	3.94e-06	0.000114	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KRAS—uterine cancer	3.94e-06	0.000114	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—PIK3CA—uterine cancer	3.91e-06	0.000113	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—uterine cancer	3.89e-06	0.000113	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KRAS—uterine cancer	3.87e-06	0.000112	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PIK3CA—uterine cancer	3.87e-06	0.000112	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PIK3CA—uterine cancer	3.83e-06	0.000111	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—uterine cancer	3.78e-06	0.00011	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—uterine cancer	3.76e-06	0.000109	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—uterine cancer	3.75e-06	0.000109	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PIK3CA—uterine cancer	3.74e-06	0.000108	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—uterine cancer	3.73e-06	0.000108	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PIK3CA—uterine cancer	3.72e-06	0.000108	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NRAS—uterine cancer	3.72e-06	0.000108	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PIK3CA—uterine cancer	3.62e-06	0.000105	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—uterine cancer	3.62e-06	0.000105	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—HRAS—uterine cancer	3.62e-06	0.000105	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—uterine cancer	3.6e-06	0.000104	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—HRAS—uterine cancer	3.58e-06	0.000104	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KRAS—uterine cancer	3.57e-06	0.000103	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PIK3CA—uterine cancer	3.56e-06	0.000103	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—uterine cancer	3.55e-06	0.000103	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—uterine cancer	3.53e-06	0.000102	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KRAS—uterine cancer	3.51e-06	0.000102	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PIK3CA—uterine cancer	3.51e-06	0.000102	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KRAS—uterine cancer	3.51e-06	0.000102	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—uterine cancer	3.5e-06	0.000101	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—uterine cancer	3.5e-06	0.000101	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KRAS—uterine cancer	3.5e-06	0.000101	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KRAS—uterine cancer	3.48e-06	0.000101	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—HRAS—uterine cancer	3.46e-06	0.0001	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KRAS—uterine cancer	3.45e-06	0.0001	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—uterine cancer	3.44e-06	9.98e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KRAS—uterine cancer	3.44e-06	9.97e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—HRAS—uterine cancer	3.44e-06	9.97e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—HRAS—uterine cancer	3.35e-06	9.69e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—HRAS—uterine cancer	3.29e-06	9.54e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3CA—uterine cancer	3.28e-06	9.51e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CA—uterine cancer	3.23e-06	9.35e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CA—uterine cancer	3.22e-06	9.33e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CA—uterine cancer	3.21e-06	9.3e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CA—uterine cancer	3.2e-06	9.27e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KRAS—uterine cancer	3.2e-06	9.26e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—uterine cancer	3.19e-06	9.25e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—uterine cancer	3.17e-06	9.2e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CA—uterine cancer	3.17e-06	9.18e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—uterine cancer	3.16e-06	9.16e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CA—uterine cancer	3.16e-06	9.16e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—uterine cancer	3.13e-06	9.06e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—uterine cancer	3.12e-06	9.05e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—uterine cancer	3.12e-06	9.03e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—uterine cancer	3.11e-06	9e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—uterine cancer	3.1e-06	8.97e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—uterine cancer	3.07e-06	8.88e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—uterine cancer	3.06e-06	8.86e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—uterine cancer	3.05e-06	8.84e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—uterine cancer	3.04e-06	8.8e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—HRAS—uterine cancer	3.04e-06	8.8e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—HRAS—uterine cancer	2.99e-06	8.65e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—HRAS—uterine cancer	2.98e-06	8.64e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—HRAS—uterine cancer	2.97e-06	8.61e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—HRAS—uterine cancer	2.96e-06	8.58e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—uterine cancer	2.95e-06	8.56e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CA—uterine cancer	2.94e-06	8.51e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—HRAS—uterine cancer	2.93e-06	8.5e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—HRAS—uterine cancer	2.93e-06	8.47e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—uterine cancer	2.91e-06	8.42e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—uterine cancer	2.87e-06	8.31e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—uterine cancer	2.84e-06	8.23e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—HRAS—uterine cancer	2.72e-06	7.87e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—uterine cancer	2.68e-06	7.77e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—uterine cancer	2.64e-06	7.64e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—uterine cancer	2.63e-06	7.62e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—uterine cancer	2.62e-06	7.6e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—uterine cancer	2.62e-06	7.58e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—uterine cancer	2.59e-06	7.5e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—uterine cancer	2.58e-06	7.48e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—uterine cancer	2.4e-06	6.95e-05	CbGpPWpGaD
